Janssen plans to expand pharma investment in China

Janssen, the pharmaceutical company, will expand its investment in China to drive growth as it races to seize more market shares in lung-related diseases.

Part of the Johnson & Johnson group, Janssen will focus on developing medicines, including drugs to fight lung disease, which is a major problem in the country.

"We will launch these drugs in the Chinese market before going global," said William N Hait, global head of Janssen’s research & development division.

To combat lung cancer, Johnson & Johnson aim to set up a global research and development center in the country.

Through innovative methods, the center hopes to lower the cases of lung cancer and increase survival rates among those affected by the disease.

During the next five years, Janssen will launch more than 10 new pharmaceutical products and expand its line in 50 existing medicines.

In addition, the company will promote sustainable growth through core product mix and innovative measures.

"Johnson & Johnson has witnessed rapid development in the Chinese market. One of the major global strategies of our company is to invest in China constantly. It is estimated that the R&D will continue to play an essential role in the innovative process of Johnson & Johnson," said Alex Gorsky, chairman and chief executive officer of Johnson & Johnson.

Joaquin Duato, executive vice president and worldwide chairman of pharmaceuticals at Johnson & Johnson said, "China is one of the most important pharmaceutical markets for us globally. It is the second largest market after the United States." "We have a strong presence, including manufacturing, commercial, as well as research and development."

Johnson & Johnson owns more than 265 subsidiaries in more than 60 countries and regions worldwide.